Key facts
- ExoCoBio’s last known valuation is $510K.
- It has raised $55.3M; the latest was Secondary Transaction - Private ($70K) in Sep 2025.
- Notable investors include SBI Investment, Korea Investment Partners, InterVest, KDB Capital, T.S. Investment — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for ExoCoBio
- ·The full record, as it builds
Funding rounds
No funding rounds for ExoCoBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ExoCoBio
Developer of regenerative medicine and biopharmaceuticals designed to create value for the healthy life of mankind. The company's products specialize in the development of stem cell-derived exosome therapeutics which are nano-vesicles secreted by cells for intercellular signalings for the growth of skin and hair, enabling clinicians to develop stimulation of cellular tissue regeneration technology alternatives.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 104
- Website
- exocobio.com/
- Ownership
- Privately Held (backing)
ExoCoBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ExoCoBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ExoCoBio in its N-PORT filings yet. We sweep new filings monthly.